Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2003 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00005025
First received: April 6, 2000
Last updated: November 5, 2013
Last verified: March 2003

April 6, 2000
November 5, 2013
June 2000
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00005025 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
A Phase II Trial of In Vivo Gene Therapy With the Herpes Simplex Thymidine Kinase for the Treatment of Ovarian Cancer

RATIONALE: Gene therapy may make the body build an immune response to kill tumor cells.

PURPOSE: Phase II trial to study the effectiveness of gene therapy in treating women who have refractory or relapsed ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer.

OBJECTIVES:

  • Determine the efficacy and safety of in vivo gene therapy with herpes simplex thymidine kinase (HSVtk) vector producer cells (VPC) followed by ganciclovir in women with refractory or relapsed ovarian epithelial adenocarcinoma, fallopian tube cancer, or peritoneal cancer.
  • Determine any development of systemic immunity to this regimen or tumor in these patients.
  • Determine the toxic effects of intraperitoneal HSVtk VPC in these patients.

OUTLINE: All patients receive an intraperitoneal catheter prior to infusion.

Patients receive herpes simplex thymidine kinase (HSVtk) vector producer cells (VPC) IP over 15-60 minutes on day 0, followed by ganciclovir IV 2 times daily on days 28-41. Treatment repeats for up to 3 courses in patients with stable or responsive disease.

Patients are followed every 3 months for 1 year.

PROJECTED ACCRUAL: A total of 14-20 patients will be accrued for this study within 18-24 months.

Interventional
Phase 2
Primary Purpose: Treatment
  • Fallopian Tube Cancer
  • Ovarian Cancer
  • Primary Peritoneal Cavity Cancer
  • Biological: herpes simplex thymidine kinase
  • Drug: ganciclovir
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
Not Provided
Not Provided
Not Provided

DISEASE CHARACTERISTICS:

  • Histologically confirmed, refractory or relapsed, ovarian epithelial adenocarcinoma, fallopian tube cancer, or extraovarian peritoneal cancer for which no curative therapy exists

    • Must have tissue available from tumor biopsy to grow tumor cells ex vivo
    • Must have failed standard therapy with both a platinum agent (cisplatin or carboplatin) and paclitaxel
  • Site of disease must be less than 5 cm in greatest diameter
  • Evaluable disease by CT scan, physical exam, or laparoscopy
  • No significant peritoneal fibrosis either from disease or prior surgery

    • Surgical lysis of adhesions allowed

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • ECOG 0-2

Life expectancy:

  • Not specified

Hematopoietic:

  • WBC greater than 2,000/mm3
  • Absolute neutrophil count at least 1,000/mm3
  • Platelet count at least 50,000/mm3
  • Hemoglobin at least 8.5 g/dL (without transfusion)

Hepatic:

  • Bilirubin no greater than 2.0 mg/dL
  • SGOT or SGPT no greater than 4 times upper limit of normal (ULN)
  • Alkaline phosphatase no greater than 4 times ULN
  • Hepatitis B surface antigen test required prior to study if transaminases greater than 2.0 times ULN
  • No hepatitis B surface antigen
  • Amylase normal
  • PT and PTT normal

Renal:

  • Creatinine no greater than 2.0 mg/dL OR
  • Creatinine clearance at least 50 mL/min

Cardiovascular:

  • No cardiac dysfunction by history and exam
  • No ischemic heart disease that may be considered anesthetic or operative risk

Pulmonary:

  • No lung disease that may be considered anesthetic or operative risk

Other:

  • HIV negative
  • Not pregnant or nursing
  • No acute viral, bacterial, or fungal infection requiring medication within 14 days prior to study
  • No patient with greater than 2 L of ascites at the time of intraperitoneal infusion
  • No underlying condition that would preclude compliance
  • No allergies to study reagent

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • Not specified

Chemotherapy:

  • See Disease Characteristics
  • No concurrent chemotherapy

Endocrine therapy:

  • Not specified

Radiotherapy:

  • Not specified

Surgery:

  • See Disease Characteristics

Other:

  • No concurrent high dose vitamin regimens
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00005025
CDR0000067546, HGTRI-0105, NCI-V00-1584
Not Provided
Not Provided
John Stoddard Cancer Center at Iowa Methodist Medical Center
Not Provided
Study Chair: Charles Joseph Link, MD John Stoddard Cancer Center at Iowa Methodist Medical Center
National Cancer Institute (NCI)
March 2003

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP